This is Pridgen's protocol. Antiviral with anti inflammatory. I took the info below from PR
Dr. Pridgen's had 9 cocktail mix patents are showing up all August 13, 2013:
I found Dr. Pridgen's 9 pending patents for his cocktail mixes!!!!!!
1) VALACICLOVIR AND CELECOXIB COMBINATION
2) VALACICLOVIR AND DICLOFENAC COMBINATION
3) ACICLOVIR AND DICLOFENAC COMBINATION
4) ACICLOVIR AND CELECOXIB COMBINATION
5) FAMCICLOVIR AND DICLOFENAC COMBINATION
6) ACICLOVIR AND MELOXICAM COMBINATION
7) FAMCICLOVIR AND MELOXICAM COMBINATION
8) VALACICLOVIR AND MELOXICAM COMBINATION
9) ANTIVIRAL COMPOUND AND COX-2 INHIBITOR COMBINATION INCLUDING COMBINATION OF FAMCICLOVIR AND CELECOXIB
2) Where the research results are NOT being found easily under Dr. Pridgen's name, studies are being found up his associate professor's name... Dr. Carol Duffy
Carol Duffy received a Ph.D. in Microbiology from the University of Iowa in 2000 and completed her postdoctoral research at Cornell University. She was appointed Assistant Professor at the University of Alabama in 2007, and Associate Professor in 2013.
My research interests lie in elucidating the mechanisms used by herpes simplex virus type 1 (HSV-1) to replicate within its host. The herpesviruses have been co-evolving with their hosts for millions of years, and have consequently developed elaborate mechanisms for replication and evasion of their hosts’ defense systems. HSV-1 is a neurotropic herpesvirus that infects ~80% of young adults worldwide. Infection of its human host is initiated with a lytic infection of the mucosal epithelium and continues through invasion of the peripheral nervous system that usually leads to establishment of a reactivatable latent infection. On occasion, HSV-1 spreads to the central nervous system, causing the most common type of sporadic viral encephalitis seen in western countries. In addition, HSV-1 can infect the corneal epithelium, causing a disease known as herpes simplex keratitis that often results in vision damage.
HSV-1 contains a structure unique to all herpesviruses called the tegument, which is composed of 20+ viral and cellular proteins packaged into virions between the capsid and envelope. Tegument proteins play a variety of roles in infection including the regulation of viral and host gene expression and the promotion of virus assembly and egress. Many tegument proteins are synthesized late in infection at the time of virus assembly. Upon infection, both the genome-containing capsid and the tegument proteins are released into the host cell. Thus tegument proteins can potentially exert their activities at both very early times prior to viral gene expression, and late times when they are produced in high amounts.
Studies in my lab focus on determining the roles of the various tegument proteins during HSV-1 replication and the mechanisms by which those roles are carried out. To this end, we utilize techniques in genetics, molecular biology, cell biology, biochemistry, microscopy, genomics, and proteomics. HSV-1 provides an excellent research system due to its short replication cycle and ease of culture. In addition there are a large number of available mutant HSV-1 strains, and with the development of the HSV-1 Bacterial Artificial Chromosome system, new mutants are easily designed and generated.
Selected Publications by Dr. Duffy
Mbong EF, Woodley L, Dunkerley E, Schrimpf JE, Morrison LA, Duffy C. Deletion of the herpes simplex virus 1 UL49 gene results in mRNA and protein translation defects that are complemented by secondary mutations in UL41. J Virol. 2012 Nov;86(22):12351-61.
Dewberry EJ, Dunkerley E, Duffy C. Purification of full-length VP22 from cells infected with HSV-1: A two-pronged approach for the solubilization and purification of viral proteins for use in biochemical studies. J Virol Methods. 2012 Aug;183(2):180-5.
Mbong EF, Woodley L, Frost E, Baines JD, Duffy C. Deletion of UL21 causes a delay in the early stages of the herpes simplex virus 1 replication cycle. J Virol. 2012 Jun;86(12):7003-7.
Duffy C, Mbong EF, Baines JD. VP22 of herpes simplex virus 1 promotes protein synthesis at late times in infection and accumulation of a subset of viral mRNAs at early times in infection. J Virol. 2009 Jan;83(2):1009-17.
Duffy C, Lavail JH, Tauscher AN, Wills EG, Blaho JA, Baines JD. Characterization of a UL49-null mutant: VP22 of herpes simplex virus type 1 facilitates viral spread in cultured cells and the mouse cornea. J Virol. 2006 Sep;80(17):8664-75.